The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression

American Journal of Hematology

Volumn 87, Issue 1, 2012, Pages 26-31

  Xiao, Li ^a   Qi, Zhu ^b   Qiusheng, Chen ^c   Li, Xu ^a   Luxi, Song ^a   Lingyun, Wu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CYCLOSPORIN A; HLA DR15 ANTIGEN; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; CHROMOSOME ABERRATION; COLON CANCER; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FEMALE GENITAL TRACT TUMOR; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERNATIONAL PROSTATE SYMPTOM SCORE; KARYOTYPE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SCHOOL CHILD; SPLEEN DISEASE; T LYMPHOCYTE; TH1 CELL; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOUS PLEURISY;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; BONE MARROW CELLS; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CYCLOSPORINE; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; T-LYMPHOCYTES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84155162512     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22184     Document Type: Article

References (22)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872-85.
2. Barrett AJ, Sloand E, Young NS. Immunologic mechanisms and treatment of myelodysplastic syndromes. In: Greenberg PL, editor. Myelodysplastic Syndromes, Clinical and Biological Advances. Cambridge, UK: Cambridge University Press; 2006. pp 147-172.
3. Sloand EM, Olnes MJ, Shenoy A, et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol 2010; 28: 5166-5173.
4. Greenberg PL, Attar E, Bennett JM, et al. NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes. Version 2, 2010. Available at: Accessed November 4, 2010.
5. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
6. Steensma DP, Dispenzieri A, Moore SB, et al. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 2003; 101: 2156-2158.
7. Jonásova A, Neuwirtová R, Cermák J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998; 100: 304-309.
8. Catalano L, Selleri C, Califano C, et al. Prolonged response to cyclosporine-A in hypoplastic refractory anemia and correlation with in vitro studies. Haematologica 2000; 85: 133-138.
9. Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137: 156-163.
10. Shimamoto T, Tohyama K, Okamoto T, et al. Cyclosporin A therapy for patients with myelodysplastic syndrome: Multicenter pilot studies in Japan. Leuk Res 2003; 27: 783-788.
11. Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 2007; 21: 1436-1441.
12. Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008; 26: 2505-2511.
13. Valent P, Horny HP. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: Update and open questions. Eur J Clin Invest 2009; 39: 548-553.
14. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15(DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002; 100: 1570-1574.
15. Xiao L, Luxi S, Ying T, et al. Diagnosis of unknown nonhematological tumors by bone marrow biopsy: A retrospective analysis of 10, 112 samples. J Cancer Res Clin Oncol 2009; 135: 687-693.
16. Wu L, Li X, Chang C, et al. Deviation of type I and type II T cells and its negative effect on hematopoiesis in myelodysplastic syndrome. Int J Lab Hematol 2008; 30: 390-399.
17. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108: 1497-1503.
18. Xiao L, Qiong L, Yan Z, et al. Experimental and clinical characteristics in myelodysplastic syndrome patients with or without HLA-DR15 allele. Hematol Oncol 2010; 28: 98-103.
19. Selleri C, Maciejewski JP, Catalano L, et al. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: In vitro and In vivo studies. Cancer 2002; 95: 1911-1922.
20. Zheng Z, Feng X, Xiao L, et al. Removal of autologous activated CD4-positive T lymphocytes also results in increased colony-forming units in patients with low and intermediate-1 risk myelodysplastic syndromes. Eur J Haematol 2011; 86: 47-56.
21. Sloand EM, Mainwaring L, Fuhrer M, et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005; 106: 841-851.
22. Zheng Z, Qianqiao Z, Qi H, et al. In vitro deprivation of CD8(+)CD57(+) T cells promotes the malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome. Exp Hematol 2010; 38: 677-684.